The works council and supervisory board at the Organon pharmaceuticals works in Oss have voted in favour of a new plan to reorganise operations which means some research work will continue in the town.

Owner Merck had planned to shut all R&D operations in Oss with the loss of over 1,000 jobs. Closing a production line will add another 1,000 plus redundancies.
Now, Merck has agreed some 486 research jobs will remain at the plant to focus on medicines for developing markets.
Officials hope this will act as a stimulus to bring other pharmaceutical firms to the town in the form of a life sciences park.